Cipla stock rises after launching Yurpeak for obesity and type 2 diabetes treatmentCipla stock rises after launching Yurpeak for obesity and type 2 diabetes treatment

Introduction

Leading pharmaceutical company launched Yurpeak® (tirzepatide), a weekly injectable therapy for obesity and type 2 diabetes, available in six strengths, aiming to expand access and patient support across India.

Also Read: Vintage Coffee and Beverages jumps after MoU at Telangana Rising Summit for 20-acre FDC project

Share price movement of Cipla

On December 11, 2025, Cipla Ltd opened at ₹1,500.65, up 0.77% from its previous close of ₹1,489.15. The stock reached a high of ₹1,508.00 (1.27%) and a low of ₹1,492.80. By 12:20 PM, it traded at ₹1,505.05, a 1.07% increase, with a market cap of ₹1,21,573.61 crore.

Cipla Launches Yurpeak for Obesity and Diabetes

Cipla Limited launched Yurpeak® (tirzepatide), a one-weekly injectable therapy for obesity and type 2 diabetes. The launch follows DCGI approval for distribution in India.

Yurpeak® is the second tirzepatide brand in India. It targets dual GIP and GLP-1 receptors and is indicated as an adjunct to diet and exercise for adults with obesity or overweight.

The therapy will be available in six strengths using the KwikPen® device. Cipla will distribute and promote Yurpeak®, with Lilly supplying the product and price aligned with Mounjaro®.

Stock performance of Cipla for Period of 1 week, 6 months, and 1 year

Cipla Ltd delivered a -1.98% return over the past week, it declined by 0.95% in the past six months. The stock gained 2.53% over the past year.

Also Read: Adani Airport Holdings jumps after completing 99% acquisition of AGHPort Aviation Services

Shareholding pattern of Cipla

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	29.20%	29.20%	29.20%
FII	24.50%	25.20%	26.30%
DII	30.30%	29.30%	28.20%
Public	16.00%	16.30%	16.40%

About Cipla

Cipla Ltd (NSE: CIPLA), established in 1935, is a global pharmaceutical company with 46 manufacturing sites, offering 1,500+ products across 80+ markets, specializing in respiratory, antiretroviral, urology, cardiology, anti-infective, and CNS segments.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs